Synergism Between Interleukin-6 and Interleukin-3 in Supporting Proliferation of Human Hematopoietic Stem Cells: Comparison with Interleukin-1 Alpha
Overview
Affiliations
Currently available evidence suggests that in the steady state, the majority of hematopoietic stem cells are dormant in cell cycle and reside in the so-called G0 period. Studies in our laboratory indicated that once a stem cell leaves G0, its subsequent proliferation requires the presence of interleukin-3 (IL-3). Recently it was reported that interleukin-1 (IL-1) may stimulate stem cells to become sensitive to IL-3. In a separate study, we observed that interleukin-6 (IL-6, also known as B cell stimulatory factor-2/interferon beta 2) possesses synergism with IL-3, shortening the G0 period of murine hematopoietic stem cells. We report here that human IL-6 and IL-3 act synergistically in support of the proliferation of progenitors for human blast cell colonies and that IL-1 alpha reveals no synergism with IL-3 when tested against purified human marrow progenitors. Panned My-10+ human marrow cells were plated in culture and on day 14 of incubation, either IL-3, IL-6, IL-1 alpha or a combination of these factors was added to the cultures. Blast cell colony formation was analyzed daily between days 18 and 32 of culture. IL-6 or IL-1 alpha alone failed to support blast cell colony formation. In the presence of IL-3 alone, blast cell colonies continued to emerge between days 21 and 27. When a combination of IL-3 and IL-6 was added, blast cell colonies developed earlier than in cultures with IL-3 alone and twice as many blast cell colonies were identified. IL-1 alpha failed to augment IL-3-dependent blast cell colony formation. Replating studies of the individual blast cell colonies revealed various types of single as well as multilineage colonies. These observations suggest that IL-6 shortens the G0 period of human hematopoietic stem cells and that the reported synergistic activities of IL-1 on primitive hematopoietic cells may be indirect.
Interleukin 6 Antagonists in Severe COVID-19 Disease: Cardiovascular and Respiratory Outcomes.
Khan S Protein Pept Lett. 2024; 31(3):178-191.
PMID: 38375841 DOI: 10.2174/0109298665266730240118054023.
Hu R, Ling X, Yang T, Zhang J, Gu X, Li F Clin Exp Med. 2023; 23(8):4623-4632.
PMID: 37925379 DOI: 10.1007/s10238-023-01242-7.
Generation of Red Blood Cells from Human Pluripotent Stem Cells-An Update.
Lee S, Jung C, Oh J, Kim S, Lee S, Lee J Cells. 2023; 12(11).
PMID: 37296674 PMC: 10253210. DOI: 10.3390/cells12111554.
The cytokine network in acute myeloid leukemia.
Luciano M, Krenn P, Horejs-Hoeck J Front Immunol. 2022; 13:1000996.
PMID: 36248849 PMC: 9554002. DOI: 10.3389/fimmu.2022.1000996.
In vitro production of functional immune cells derived from human hematopoietic stem cells.
Payuhakrit W, Panichakul T, Charoenphon N, Chalermsaenyakorn P, Jaovisidha A, Wongborisuth C EXCLI J. 2016; 14:1031-9.
PMID: 26933404 PMC: 4763471. DOI: 10.17179/excli2015-506.